Nebenwirkungen · Datroway
Datroway 100 mg powder for concentrate for solution for infusion · Abschnitt 4.8 · PDF-Seite 10
HOS-153451 · Präparat HOS-100992
Stomatitis occurred in 64.3% of the pool of patients treated with Datroway, of which 29.1% were Grade 1, 27.1% were Grade 2 and 8.1% were Grade 3. Median time to first onset was 0.7 months (range: 0.03 to 19.8) and with a median duration of 1.1 months (range: 0.03 to 25.5). Discontinuation due to stomatitis occurred in 0.2% of patients.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2026-09-30T15:20:00Z · SHA-256 2af2f3f5780300dcbd1cf2c5d2f2a45c37c2f1201a201c3988247b9015cd89e5 · Passage 85553b053fd3c95634fd7f32be0f17948439bef2d2bd130425067c4f4bedc76a · Zeichen 8729–9067 im Abschnitt